Mark Heiman

Mark Heiman has held various roles in the field of biosciences and therapeutics. Mark started their career at Eli Lilly and Company in 1987 as a Senior Scientist and eventually became a Research Fellow. During their time at Eli Lilly, they served as the CSO for Obesity and made significant contributions to the company's research and development efforts. In 2010, they joined Microbiome Therapeutics as the CSO and remained in this role until 2018. Currently, they serve as the CSO at Scioto Biosciences, Inc. Overall, Mark Heiman brings extensive experience and expertise in the field of biosciences and therapeutics.

Mark Heiman attended the University of New Orleans from 1970 to 1974, where they earned a Bachelor's degree in Biology, General. Following this, from 1974 to 1978, they studied at the Louisiana State University School of Medicine in New Orleans, where they obtained a Doctor of Philosophy (Ph.D.) in Human Physiology.